FindTrial
Sign In

Interferon beta

DRUG5 trials

Sponsors

FDA Office of Orphan Products Development, Heidelberg University, Faron Pharmaceuticals Ltd, Biogen

Conditions

Acute Lung InjuryAcute Respiratory Distress SyndromeAdrenoleukodystrophyMacular EdemaMultiple SclerosisRelapsing Multiple SclerosisUveitis, Intermediate

Phase 1

Safety, Tolerability and Preliminary Efficacy of FP-1201 in ALI and ARDS. Phase I/II
CompletedNCT00789685
Faron Pharmaceuticals LtdAcute Lung Injury, Acute Respiratory Distress Syndrome
Start: 2009-02-28End: 2011-09-30Updated: 2015-05-27

Phase 3

Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis
CompletedNCT00344253
Heidelberg UniversityMacular Edema, Multiple Sclerosis, Uveitis, Intermediate
Start: 2006-03-31End: 2012-01-31Updated: 2012-12-03

Phase 4

Transition to Peginterferon Beta-1a (BIIB017) From Subcutaneous Interferon Therapy
WithdrawnNCT02234869
BiogenRelapsing Multiple Sclerosis
Start: 2014-10-31End: 2018-03-31Updated: 2014-11-17

Unknown Phase

Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy
CompletedNCT00004450
FDA Office of Orphan Products DevelopmentAdrenoleukodystrophy
Start: 1998-08-31End: 2000-11-30Target: 60Updated: 2015-03-25
A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies
RecruitingNCT05688436
BiogenMultiple Sclerosis
Start: 2021-09-24End: 2031-01-17Target: 1178Updated: 2025-10-17

Related Papers

The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study.
2013-12-23117 citations